Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Sponsor
Xinqiao Hospital of Chongqing
Study ID
NCT03190239
Phase
PHASE2
Status
Withdrawn

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib 250mg qd
  • Pemetrexed — DRUG
    Pemetrexed 500mg/m2 qm

Study Details

Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. This design is to study maintenance therapy with pemetrexed plus apatinib after first line induction therapy four cycles for advanced non-squamous non-small-cell lung cancer. XQonc-0007

Key Dates

Start date
Jul 15, 2017
Status verified
Feb 2024
Primary completion
Jul 30, 2020
Completion
Jul 30, 2020

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib XQonc-0007
    Pemetrexed 500 mg/m2, qm; Apatinib 250 mg Po qd

Primary Outcome Measure

Progression free survival（PFS） [ Time Frame: Up to two years ]

Related Studies